Gilead Sciences, Inc. (GIS.F)

73,90 -1,07 (-1,43%) Börsenschluss: 07:50PM CET

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
https://www.gilead.com

Sektor(en): Healthcare
Branche: Drug Manufacturers—General
Vollzeitmitarbeiter: 17.000

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Daniel P. O'Day	Chairman & CEO	6,09M	N/A	1964
Mr. Andrew D. Dickinson	Exec. VP & CFO	2,55M	N/A	1970
Ms. Johanna Mercier	Chief Commercial Officer	2,92M	N/A	1970
Dr. Merdad V. Parsey M.D., Ph.D.	Chief Medical Officer	2,68M	N/A	1963
Ms. Sandra Patterson	Sr. VP, Corp. Controller & Principal Accounting Officer	N/A	N/A	1967
Ms. Jacquie Ross C.F.A.	VP of Investor Relations	N/A	N/A	N/A
Ms. Deborah H. Telman	Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.	N/A	N/A	1965
Ms. Jyoti K. Mehra	Exec. VP of HR	N/A	N/A	1976
Dr. Michael Quigley Ph.D.	Sr. VP of Research Biology	N/A	N/A	N/A
Dr. Linda Slanec Higgins Ph.D.	Sr. VP & Head of External Innovation	N/A	N/A	1962

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Corporate Governance

Gilead Sciences, Inc.s ISS Governance QualityScore, Stand 1. März 2023, lautet 1. Die grundlegenden Scores sind Audit: 3, Vorstand: 4, Shareholderrechte: 1, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.